论文部分内容阅读
1 文献来源 M(o|¨)ricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival:Treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J].Blood,2008,111(9):4477-4489 2 证据水平 1c。 3 背景既往10年儿童急性淋巴细胞白血病的治疗已取得了显著进步,近75%的患儿可长期生存。ALLBFM为德国柏林-法兰克福-蒙斯特(Bedin-Frankfurt-M(u|¨)nster,BFM)急性淋巴细胞性白血病
1 References M (o | ¨) ricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J] .Blood, 2008,111 (9): 4477-4489 2 Level of Evidence 1c. 3 Background The treatment of childhood acute lymphoblastic leukemia has made significant progress over the past 10 years, with nearly 75% of children having long-term survival. ALLBFM was Bedin-Frankfurt-M (BFM) acute lymphoblastic leukemia